Coronavirus (COVID-19) Research
preprint: COVID-19 and Teriflunomide
COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis (May 20)
https://europepmc.org/article/ppr/ppr165674
...We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS...
https://europepmc.org/article/ppr/ppr165674
...We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS...
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
DMTs and COVID-19
Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of the International and National Recommendations (May 18)
fft: https://meridian.allenpress.com/ijmsc/a ... 20-037.pdf
"...recommendations regarding the use of DMTs during the COVID-19 outbreak from national or international MS/neurology societies were identified and reviewed... recommendations regarding DMT initiation and management during this outbreak were summarized. Moreover, the experts' views about the risk of COVID-19 infection with each DMT were discussed as well."
fft: https://meridian.allenpress.com/ijmsc/a ... 20-037.pdf
"...recommendations regarding the use of DMTs during the COVID-19 outbreak from national or international MS/neurology societies were identified and reviewed... recommendations regarding DMT initiation and management during this outbreak were summarized. Moreover, the experts' views about the risk of COVID-19 infection with each DMT were discussed as well."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
Hey,
Did you see what was going on lately ?
Summary :
Pr Raoult has developed an efficient treatment against Covid19 (hydroxychloroquine + antbiotic) .
This treatment seems to be very efficient at the early stage of the disease.
To big pharma Raoult is « the man to shoot » as :
1) His treatment is inexpensive
2) His speech is not on line with big pharma (BP was saying : we need to take the time to develop a suitable protocol to find a treatment. Raoult was saying: I am a doctor, I treat patients, people are dying, there is no time to waste, so I don’t care about your protocol.
Following that, a very violent propaganda again Raoult started.
In France, hydroxychloroquine has become a « poison » and the government has decided to forbid it’s usage for Covid19 !
Worldwide, « the Lancet » (prestigious journal) has released the result of a very wide study showing that hydroxychloroquine is killing people.
Many doctors worldwide are questionning these data and…this study appears to be completely fake !!!
The Lancet reputation is at stake !
Amazing…
Did you see what was going on lately ?
Summary :
Pr Raoult has developed an efficient treatment against Covid19 (hydroxychloroquine + antbiotic) .
This treatment seems to be very efficient at the early stage of the disease.
To big pharma Raoult is « the man to shoot » as :
1) His treatment is inexpensive
2) His speech is not on line with big pharma (BP was saying : we need to take the time to develop a suitable protocol to find a treatment. Raoult was saying: I am a doctor, I treat patients, people are dying, there is no time to waste, so I don’t care about your protocol.
Following that, a very violent propaganda again Raoult started.
In France, hydroxychloroquine has become a « poison » and the government has decided to forbid it’s usage for Covid19 !
Worldwide, « the Lancet » (prestigious journal) has released the result of a very wide study showing that hydroxychloroquine is killing people.
Many doctors worldwide are questionning these data and…this study appears to be completely fake !!!
The Lancet reputation is at stake !
Amazing…
Re: Coronavirus (COVID-19): What You Need To Know
please link your statements to verifiable, credible source material. thank you in advance ![Happy :)](./images/smilies/1.gif)
![Happy :)](./images/smilies/1.gif)
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19) (Apr 3)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204586/
...The off-label use of CQ and HCQ to treat or prevent COVID-19 must be cautious, considering potential serious toxicities. Global multicenter RCTs testing safety and efficacy of CQ or HCQ seem to be the most reasonable plan to urgently gather data on the efficacy and safety of these medications in the treatment of COVID-19. Before the availability of robust data from RCTs, we highly recommend that off-label use of medications to treat COVID-19, including CQ or HCQ, be accompanied by careful observation for potential toxicity.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204586/
...The off-label use of CQ and HCQ to treat or prevent COVID-19 must be cautious, considering potential serious toxicities. Global multicenter RCTs testing safety and efficacy of CQ or HCQ seem to be the most reasonable plan to urgently gather data on the efficacy and safety of these medications in the treatment of COVID-19. Before the availability of robust data from RCTs, we highly recommend that off-label use of medications to treat COVID-19, including CQ or HCQ, be accompanied by careful observation for potential toxicity.
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know (Mar 31)
https://www.acpjournals.org/doi/full/10.7326/M20-1334
"...The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated antiviral activity against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly controlled or uncontrolled clinical studies (1–3). Normally, such research would be deemed hypothesis-generating at best.
...
Data to support the use of HCQ and CQ for COVID-19 are limited and inconclusive. The drugs have some in vitro activity against several viruses, including coronaviruses and influenza, but previous randomized trials in patients with influenza have been negative (4, 5). In COVID-19, one small nonrandomized study from France (3) (discussed elsewhere in Annals of Internal Medicine [6]) demonstrated benefit but had serious methodological flaws, and a follow-up study still lacked a control group. Yet, another very small, randomized study from China in patients with mild to moderate COVID-19 found no difference in recovery rates (7). Sadly, reports of adverse events have increased, with several countries reporting poisonings and at least 1 death reported in a patient who drank fish tank cleaner because of its CQ content. Antimalarial drugs can cause ventricular arrhythmias, QT prolongation, and other cardiac toxicity, which may pose particular risk to critically ill persons. Given these serious potential adverse effects, the hasty and inappropriate interpretation of the literature by public leaders has potential to do serious harm. At this time of crisis, it is our ethical obligation as physicians and researchers to organize and refer patients to expedited, well-performed randomized trials that can clarify if, when, and for whom antimalarial medications are helpful in COVID-19. As of this writing, 10 such trials are under way, and information should be forthcoming within weeks."
https://www.acpjournals.org/doi/full/10.7326/M20-1334
"...The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated antiviral activity against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly controlled or uncontrolled clinical studies (1–3). Normally, such research would be deemed hypothesis-generating at best.
...
Data to support the use of HCQ and CQ for COVID-19 are limited and inconclusive. The drugs have some in vitro activity against several viruses, including coronaviruses and influenza, but previous randomized trials in patients with influenza have been negative (4, 5). In COVID-19, one small nonrandomized study from France (3) (discussed elsewhere in Annals of Internal Medicine [6]) demonstrated benefit but had serious methodological flaws, and a follow-up study still lacked a control group. Yet, another very small, randomized study from China in patients with mild to moderate COVID-19 found no difference in recovery rates (7). Sadly, reports of adverse events have increased, with several countries reporting poisonings and at least 1 death reported in a patient who drank fish tank cleaner because of its CQ content. Antimalarial drugs can cause ventricular arrhythmias, QT prolongation, and other cardiac toxicity, which may pose particular risk to critically ill persons. Given these serious potential adverse effects, the hasty and inappropriate interpretation of the literature by public leaders has potential to do serious harm. At this time of crisis, it is our ethical obligation as physicians and researchers to organize and refer patients to expedited, well-performed randomized trials that can clarify if, when, and for whom antimalarial medications are helpful in COVID-19. As of this writing, 10 such trials are under way, and information should be forthcoming within weeks."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
https://www.theguardian.com/world/2020/ ... fessionals
More than 120 researchers and medical professionals from around the world have written an open letter to the editor of the Lancet raising serious concerns about a large and widely publicised global study that prompted the World Health Organisation to halt several Covid-19 clinical trials.
“There was no ethics review,” the letter continues. “There was no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions. A request to the authors for information on the contributing centres was denied. Data from Australia are not compatible with government reports.
The letter also expressed concern about unusually small reported variances in baseline variables, interventions and outcomes between continents, despite significant differences in demographics.
Re: Coronavirus (COVID-19): What You Need To Know
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID‐19 (May 2)
https://onlinelibrary.wiley.com/doi/ful ... acem.14005
"...There are currently seven completed clinical trials and 29 registered clinical trials focusing on HCQ or CQ as a therapeutic avenue for COVID‐19. Of these, five of seven trials have shown favorable outcomes for patients using CQ or HCQ and two of seven have shown no change compared to control. However, all seven trials carried varying degrees of bias and poor study design.
...
There are currently not enough data available to support the routine use of HCQ and CQ as therapies for COVID‐19. Pending further results from more extensive studies with more stringent study parameters, clinicians should defer from routine use of HCQ and CQ. There are several clinical trials currently under way with results expected soon."
https://onlinelibrary.wiley.com/doi/ful ... acem.14005
"...There are currently seven completed clinical trials and 29 registered clinical trials focusing on HCQ or CQ as a therapeutic avenue for COVID‐19. Of these, five of seven trials have shown favorable outcomes for patients using CQ or HCQ and two of seven have shown no change compared to control. However, all seven trials carried varying degrees of bias and poor study design.
...
There are currently not enough data available to support the routine use of HCQ and CQ as therapies for COVID‐19. Pending further results from more extensive studies with more stringent study parameters, clinicians should defer from routine use of HCQ and CQ. There are several clinical trials currently under way with results expected soon."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
thanks zen, for your link to an article from a credible media source, concerning a letter and article of interest.
please also provide a link to the original article discussed, and to the resulting commentary letter.
please also provide a link to the original article discussed, and to the resulting commentary letter.
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
Need for Abundant Caution in Prophylactic Application of Chloroquine and Hydroxychloroquine for Viral Infections Including COVID-19: Possibility of Increased Susceptibility (Apr 7)
https://papers.ssrn.com/sol3/papers.cfm ... id=3570607
fft: https://bit.ly/2zBerGO
"...Concern 1: Increased risk of all infections (including COVID-19) from CQ/HCQ mediated immuno-suppression and
immuno-modulation
...
Concern 2: Increased malarial resistance to CQ and HCQ
...
Concern 3: Unavailability of CQ and HCQ for other critical therapies
...
Concern 4: Side-effects of CQ and HCQ
...
Conclusion
Abundant caution needs to be exercised in recommending and using CQ and HCQ as prophylactic agents for COVID-19, especially in the light of their well-recorded immuno-suppressive and immuno-modulatory properties, as well as repeated verification of inefficacy against viral infection and replication in vivo. This is not to persuade against therapeutic application of CQ and HCQ for their anti-inflammatory properties to mitigate SARS-CoV-2 induced pneumonia and inflammatory immuno-hyperactivity."
https://papers.ssrn.com/sol3/papers.cfm ... id=3570607
fft: https://bit.ly/2zBerGO
"...Concern 1: Increased risk of all infections (including COVID-19) from CQ/HCQ mediated immuno-suppression and
immuno-modulation
...
Concern 2: Increased malarial resistance to CQ and HCQ
...
Concern 3: Unavailability of CQ and HCQ for other critical therapies
...
Concern 4: Side-effects of CQ and HCQ
...
Conclusion
Abundant caution needs to be exercised in recommending and using CQ and HCQ as prophylactic agents for COVID-19, especially in the light of their well-recorded immuno-suppressive and immuno-modulatory properties, as well as repeated verification of inefficacy against viral infection and replication in vivo. This is not to persuade against therapeutic application of CQ and HCQ for their anti-inflammatory properties to mitigate SARS-CoV-2 induced pneumonia and inflammatory immuno-hyperactivity."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
Rethinking the role of hydroxychloroquine in the treatment of COVID‐19 (Apr 29)
https://faseb.onlinelibrary.wiley.com/d ... .202000919
"...Given these facts and the growing uncertainty about these agents for the treatment of COVID‐19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID‐19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case‐by‐case basis after rigorous consideration of the risks and benefits of this therapeutic approach."
https://faseb.onlinelibrary.wiley.com/d ... .202000919
"...Given these facts and the growing uncertainty about these agents for the treatment of COVID‐19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID‐19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case‐by‐case basis after rigorous consideration of the risks and benefits of this therapeutic approach."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
preprint: Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea (May 18)
https://www.medrxiv.org/content/10.1101 ... 20089904v2
"... Among the 65,149 eligible subjects (mean age, 48.3 years; 49.4% male), 5,172 (7.9%) were diagnosed with COVID-19. Hydroxychloroquine was not significantly associated with the risk of COVID-19 (adjusted odds ratio [aOR], 1.48; 95% CI, 0.95-2.31). In the overall population, lower risks of COVID-19 were associated with the use of camostat (aOR, 0.45; 95% CI, 0.20-1.02) and amiodarone (aOR, 0.54; 95% CI, 0.33-0.89), although the differences were not significant in the subgroup analyses.
...
Conclusions. No medications were consistently associated with increased or decreased risks of COVID-19. These findings suggest that a more cautious approach is warranted for the clinical use of re-purposed drugs until the results are available from clinical trials."
https://www.medrxiv.org/content/10.1101 ... 20089904v2
"... Among the 65,149 eligible subjects (mean age, 48.3 years; 49.4% male), 5,172 (7.9%) were diagnosed with COVID-19. Hydroxychloroquine was not significantly associated with the risk of COVID-19 (adjusted odds ratio [aOR], 1.48; 95% CI, 0.95-2.31). In the overall population, lower risks of COVID-19 were associated with the use of camostat (aOR, 0.45; 95% CI, 0.20-1.02) and amiodarone (aOR, 0.54; 95% CI, 0.33-0.89), although the differences were not significant in the subgroup analyses.
...
Conclusions. No medications were consistently associated with increased or decreased risks of COVID-19. These findings suggest that a more cautious approach is warranted for the clinical use of re-purposed drugs until the results are available from clinical trials."
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
preprint: Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review (May 11)
https://www.medrxiv.org/content/10.1101 ... 20094326v1
..Outcomes most commonly reported were improved lung function, viral clearance, and hospital discharge. Strong evidence to support the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 is lacking. Fast track trials are riddled with bias and may not conform to rigorous guidelines which may lead to inadequate data being reported. The use of these drugs in combination with other medications may be useful but without knowing which groups they are suited for and when, they may cause more harm than good.
https://www.medrxiv.org/content/10.1101 ... 20094326v1
..Outcomes most commonly reported were improved lung function, viral clearance, and hospital discharge. Strong evidence to support the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 is lacking. Fast track trials are riddled with bias and may not conform to rigorous guidelines which may lead to inadequate data being reported. The use of these drugs in combination with other medications may be useful but without knowing which groups they are suited for and when, they may cause more harm than good.
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
Re: Coronavirus (COVID-19): What You Need To Know
Here can be found Dr Raoult's Marseille study of hydroxychloroquine.
Updated proofs of our paper published in Travel Medicine and Infectious Disease : "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France." https://sciencedirect.com/science/artic ... 3920302179… Abstract
Background
In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19.
Methods
We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days).
Results
A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).
Conclusion
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.
Keywords
SARS-CoV-2
COVID-19
Hydroxychloroquine
Azithromycin
Updated proofs of our paper published in Travel Medicine and Infectious Disease : "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France." https://sciencedirect.com/science/artic ... 3920302179… Abstract
Background
In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19.
Methods
We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days).
Results
A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).
Conclusion
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.
Keywords
SARS-CoV-2
COVID-19
Hydroxychloroquine
Azithromycin
Re: Coronavirus (COVID-19): What You Need To Know
repeating my previous request for one direct link to the original lancet article discussed, and one more direct link to the original response letter.
active members shape site content. if there is a problem, speak up!
use the report button to flag problematic post content to volunteer moderators' attention.
use the report button to flag problematic post content to volunteer moderators' attention.
-
- Similar Topics
- Replies
- Views
- Last post
-
- 14 Replies
- 2773 Views
-
Last post by Zyklon
-
- 0 Replies
- 1347 Views
-
Last post by vesta
-
- 2 Replies
- 1543 Views
-
Last post by NHE
-
- 0 Replies
- 1993 Views
-
Last post by vesta
-
- 0 Replies
- 1847 Views
-
Last post by tzootsi
-
- 0 Replies
- 1158 Views
-
Last post by David1949
-
- 0 Replies
- 1592 Views
-
Last post by maggieMSOC
-
- 1 Replies
- 11605 Views
-
Last post by ElliotB
-
- 0 Replies
- 1414 Views
-
Last post by NeusFunollet